Urispas Indication:

For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

Urispas Mechanism Of Action:

Urispas acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, urge incontinence episodes, urge severity and improving retention, facilitating increased volume per void.

Urispas Drug Interactions:

Donepezil Possible antagonism of action
Galantamine Possible antagonism of action
Rivastigmine Possible antagonism of action

Urispas Food Interactions:

Take without regard to meals.
Food may reduce irritation.

Urispas Generic Name:


  • Flavoxate HCI
  • Flavoxate HCL

Drug Type:

Small Molecule; Approved


Well absorbed from gastrointestinal tract.

Toxicity (Overdose):

The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.

Protein Binding:

Not Available


Not Available

Half Life:

Not Available

Dosage Forms of Urispas:

Tablet Oral

Chemical IUPAC Name:

2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate

Organisms Affected:

Humans and other mammals

Urispas to general, pharmacology

General, pharmacology..
General health